Novelion Therapeutics Inc (NVLN) Stake Lessened by BlackRock Inc.
BlackRock Inc. lowered its stake in shares of Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT) by 93.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,923 shares of the biotechnology company’s stock after selling 637,682 shares during the quarter. BlackRock Inc. owned about 0.23% of Novelion Therapeutics worth $158,000 as of its most recent SEC filing.
Separately, Healthcare Value Capital LLC increased its holdings in shares of Novelion Therapeutics by 31.3% during the second quarter. Healthcare Value Capital LLC now owns 1,313,387 shares of the biotechnology company’s stock valued at $4,833,000 after acquiring an additional 313,387 shares in the last quarter. Institutional investors and hedge funds own 73.20% of the company’s stock.
NVLN has been the topic of several recent analyst reports. Royal Bank of Canada cut their price objective on shares of Novelion Therapeutics from $6.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday, August 9th. Zacks Investment Research lowered Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. ValuEngine upgraded Novelion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Bloom Burton lowered Novelion Therapeutics from an “accumulate” rating to a “hold” rating in a research report on Wednesday, November 14th.
About Novelion Therapeutics
Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand.
See Also: Short Selling Stocks and Day Traders
Want to see what other hedge funds are holding NVLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT).
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.